TY - JOUR
T1 - A novel contact-free atrial fibrillation monitor
T2 - A pilot study
AU - Sadeh, Ben
AU - Merdler, Ilan
AU - Sadon, Sapir
AU - Lupu, Lior
AU - Borohovitz, Ariel
AU - Ghantous, Eihab
AU - Taieb, Philippe
AU - Granot, Yoav
AU - Goldstein, Orit
AU - Soriano, Jonathan Calderón
AU - Rubio-Oliver, Ricardo
AU - Ruiz-Rivas, Joaquin
AU - Zalevsky, Zeev
AU - Garcia-Monreal, Javier
AU - Shatsky, Maxim
AU - Polani, Sagi
AU - Arbel, Yaron
N1 - Publisher Copyright:
© 2021 The Author(s). Published by Oxford University Press on behalf of the European Society of Cardiology.
PY - 2022/3/1
Y1 - 2022/3/1
N2 - Aims: Atrial fibrillation (AF) is a major cause of morbidity and mortality. Current guidelines support performing electrocardiogram (ECG) screenings to spot AF in high-risk patients. The purpose of this study was to validate a new algorithm aimed to identify AF in patients measured with a recent FDA-cleared contact-free optical device. Methods and results: Study participants were measured simultaneously using two devices: A contact-free optical system that measures chest motion vibrations (investigational device, 'Gili') and a standard reference bed-side ECG monitor (Mindray®). Each reference ECG was evaluated by two board certified cardiologists that defined each trace as: regular rhythm, AF, other irregular rhythm or indecipherable/missing. A total of 3582, 30-s intervals, pertaining to 444 patients (41.9% with a history of AF) were made available for analysis. Distribution of patients with active AF, other irregular rhythm, and regular rhythm was 16.9%, 29.5%, and 53.6% respectively. Following application of cross-validated machine learning approach, the observed sensitivity and specificity were 0.92 [95% confidence interval (CI): 0.91-0.93] and 0.96 (95% CI: 0.95-0.96), respectively. Conclusion: This study demonstrates for the first time the efficacy of a contact-free optical device for detecting AF.
AB - Aims: Atrial fibrillation (AF) is a major cause of morbidity and mortality. Current guidelines support performing electrocardiogram (ECG) screenings to spot AF in high-risk patients. The purpose of this study was to validate a new algorithm aimed to identify AF in patients measured with a recent FDA-cleared contact-free optical device. Methods and results: Study participants were measured simultaneously using two devices: A contact-free optical system that measures chest motion vibrations (investigational device, 'Gili') and a standard reference bed-side ECG monitor (Mindray®). Each reference ECG was evaluated by two board certified cardiologists that defined each trace as: regular rhythm, AF, other irregular rhythm or indecipherable/missing. A total of 3582, 30-s intervals, pertaining to 444 patients (41.9% with a history of AF) were made available for analysis. Distribution of patients with active AF, other irregular rhythm, and regular rhythm was 16.9%, 29.5%, and 53.6% respectively. Following application of cross-validated machine learning approach, the observed sensitivity and specificity were 0.92 [95% confidence interval (CI): 0.91-0.93] and 0.96 (95% CI: 0.95-0.96), respectively. Conclusion: This study demonstrates for the first time the efficacy of a contact-free optical device for detecting AF.
KW - Camera
KW - Contact free
KW - Heart rate
KW - Laser
KW - Respiratory rate
KW - Vital signs
UR - http://www.scopus.com/inward/record.url?scp=85152149973&partnerID=8YFLogxK
U2 - 10.1093/ehjdh/ztab108
DO - 10.1093/ehjdh/ztab108
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 36713997
AN - SCOPUS:85152149973
SN - 2634-3916
VL - 3
SP - 105
EP - 113
JO - European Heart Journal - Digital Health
JF - European Heart Journal - Digital Health
IS - 1
ER -